Active and passive immunotherapy for neurodegenerative disorders

Developments of a water-maze procedure for studying spatial learning in the rat

Morris, R. (1984) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(84)90007-4 · Cited by 7,180 · see citing works

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · see citing works

Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · see citing works

Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · see citing works

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160 · see citing works

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · see citing works

Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · see citing works

Natural oligomers of the amyloid-β protein specifically disrupt cognitive function

Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,677 · see citing works

Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories

Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656 · see citing works

β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression

Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518 · see citing works

Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. A., Hardy, J., Duff, K., Jantzen, P. T., DiCarlo, G., Wilcock, D. M., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,488 · see citing works

Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431 · see citing works

RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain

Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426 · see citing works

Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · see citing works

Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · see citing works

Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329 · see citing works

Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease

DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · see citing works

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ ₄₂ in humans

Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246 · see citing works

Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease

Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207 · see citing works

Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695

Chishti, M. A., Yang, D.-S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100710200 · Cited by 955 · see citing works

Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults

Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · see citing works

Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model

Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858 · see citing works

Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome

Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780 · see citing works

Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease

Höck, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 777 · see citing works

Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides 1 1Edited by I. A. Wilson

Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., Hoess, A., Wölle, J., Plückthun, A., & Virnekäs, B. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3444 · Cited by 728 · see citing works

Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease

Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L. A., McKeel, D. W., & Morris, J. C. (2001) · Neurology · doi:10.1212/wnl.56.1.127 · Cited by 720 · see citing works

Amyloid precursor protein processing and Aβ 42 deposition in a transgenic mouse model of Alzheimer disease

Johnson‐Wood, K., Lee, M., Motter, R. N., Hu, K., Gordon, G., Barbour, R., Khan, K., Gordon, M. N., Tan, H. T., Games, D., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.4.1550 · Cited by 634 · see citing works

Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease

Price, J. L., Ko, A. I., Wade, M. J., Tsou, S. K., McKeel, D. W., & Morris, J. C. (2001) · Archives of Neurology · doi:10.1001/archneur.58.9.1395 · Cited by 596 · see citing works

Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease

Ferrer, I., Boada, M., Guerra, M. L. S., Rey, M. J., & Costa‐Jussà, F. R. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00493.x · Cited by 567 · see citing works

Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease

Fox, N. C., Black, R. S., Gilman, S., Rossor, M. N., Griffith, S. G., Jenkins, L., & Koller, M. (2005) · Neurology · doi:10.1212/01.wnl.0000159743.08996.99 · Cited by 550 · see citing works

Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease

Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.010 · Cited by 542 · see citing works

Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy

Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M., & Jucker, M. (2002) · Science · doi:10.1126/science.1078259 · Cited by 511 · see citing works

Monoclonal antibodies inhibit prion replication and delay the development of prion disease

White, A. R., Enever, P., Tayebi, M., Mushens, R., Linehan, J., Brandner, S., Anstee, D. J., Collinge, J., & Hawke, S. H. (2003) · Nature · doi:10.1038/nature01457 · Cited by 490 · see citing works

Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo

Klyubin, I., Walsh, D. M., Lemere, C. A., Cullen, W. K., Shankar, G. M., Betts, V., Spooner, E. T., Jiang, L., Anwyl, R., Selkoe, D. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1234 · Cited by 489 · see citing works

NEURODEGENERATIVE DISEASES: New Concepts of Pathogenesis and Their Therapeutic Implications

Skovronsky, D., Lee, V. M. ‐., & Trojanowski, J. Q. (2006) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100113 · Cited by 421 · see citing works

Disaggregation of Alzheimer β-amyloid by site-directed mAb

Solomon, B., Koppel, R., Frankel, D., & Hanan, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4109 · Cited by 420 · see citing works

Reversible memory loss in a mouse transgenic model of Alzheimer’s disease

Kotilinek, L. A., Bacskai, B., Westerman, M., Kawarabayashi, T., Younkin, L., Hyman, B. T., Younkin, S., & Ashe, K. H. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06331.2002 · Cited by 420 · see citing works

Clinical manifestations of cerebral amyloid angiopathy–related inflammation

Eng, J. A., Frosch, M. P., Choi, K., Rebeck, G. W., & Greenberg, S. M. (2004) · Annals of Neurology · doi:10.1002/ana.10810 · Cited by 417 · see citing works

Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology

Bard, F., Barbour, R., Cannon, C., Carretto, R., Fox, M., Games, D., Guido, T., Hoenow, K., Hu, K., Johnson-Wood, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0436286100 · Cited by 411 · see citing works

An inquiry into the causes and effects of the variolae vaccinae, a disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of the cow pox

Jenner, E. (2010) · Harvard Library (Harvard University) · doi:10.5281/zenodo.15162409 · Cited by 392 · see citing works

Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies

Scheff, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.002 · Cited by 391 · see citing works

Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees

Klunk, W. E., Price, J. C., Mathis, C. A., Tsopelas, N. D., Lopresti, B. J., Ziolko, S. K., Bi, W., Hoge, J. A., Cohen, A. D., Ikonomovic, M. D., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0730-07.2007 · Cited by 389 · see citing works

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage.

Wilcock, D. M., Rojiani, A. M., Rosenthal, A., Subbarao, S., Freeman, M. J., Gordon, M. N., & Morgan, D. (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-24 · Cited by 388 · see citing works

Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease

Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507892200 · Cited by 379 · see citing works

Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD

Bayer, A. J., Bullock, R., Jones, R. W., Wilkinson, D., Paterson, K. R., Jenkins, L., Millais, S. B., & Donoghue, S. (2005) · Neurology · doi:10.1212/01.wnl.0000148604.77591.67 · Cited by 356 · see citing works

Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

Masliah, E., Hansen, L., Adame, A., Crews, L. A., Bard, F., Lee, C., Seubert, P. A., Games, D., Kirby, L., & Schenk, D. (2005) · Neurology · doi:10.1212/01.wnl.0000148590.39911.df · Cited by 355 · see citing works

Prevention of Scrapie Pathogenesis by Transgenic Expression of Anti-Prion Protein Antibodies

Heppner, F. L., Musahl, C., Arrighi, I., Klein, M. A., Rülicke, T., Oesch, B., Zinkernagel, R. M., Kalinke, U., & Aguzzi, A. (2001) · Science · doi:10.1126/science.1063093 · Cited by 345 · see citing works

Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β<i>In Vivo</i>by Immunotherapy

Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Games, D., Seubert, P., Schenk, D., & Hyman, B. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-18-07873.2002 · Cited by 323 · see citing works

Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease

Benner, E. J., Mosley, R. L., Destache, C. J., Lewis, T. B., Jackson-Lewis, V. R., Gorantla, S., Nemachek, C., Green, S. R., Przedborski, S., & Gendelman, H. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400569101 · Cited by 321 · see citing works

Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β

Racke, M. M., Boone, L. I., Hepburn, D. L., Parsadainian, M., Bryan, M. T., Ness, D. K., Piroozi, K. S., Jordan, W. H., Brown, D. D., Hoffman, W. P., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4337-04.2005 · Cited by 320 · see citing works

Intravenous immunoglobulins containing antibodies against -amyloid for the treatment of Alzheimer's disease

Dodel, R. C. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.033399 · Cited by 317 · see citing works

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide.

Solomon, B., Koppel, R., Hanan, E., & Katzav-Gozansky, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.452 · Cited by 314 · see citing works

Reduction of Soluble Aβ and Tau, but Not Soluble Aβ Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles

Oddo, S., Vasilevko, V., Caccamo, A., Kitazawa, M., Cribbs, D. H., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608485200 · Cited by 282 · see citing works

Targeting Amyloid-β Peptide (Aβ) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Aβ Precursor Protein (APP) Transgenic Mice

Lee, E. B., Leng, L. Z., Zhang, B., Kwong, L. K., Trojanowski, J. Q., Abel, T. G., & Lee, V. M. ‐. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m511018200 · Cited by 252 · see citing works

Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis

Urushitani, M., Ezzi, S. A., & Julien, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606201104 · Cited by 237 · see citing works

IgG-Assisted Age-Dependent Clearance of Alzheimer's Amyloid β Peptide by the Blood–Brain Barrier Neonatal Fc Receptor

Deane, R., Sagare, A. P., Hamm, K., Parisi, M., LaRue, B., Guo, H., Wu, Z., Holtzman, D. M., & Zloković, B. V. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3697-05.2005 · Cited by 233 · see citing works

Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation

Wilcock, D. M., DiCarlo, G., Henderson, D., Jackson, J., Clarke, K., Ugen, K. E., Gordon, M. N., & Morgan, D. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-09-03745.2003 · Cited by 232 · see citing works

Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ-/-Knock-Out Mice

Das, P., HOWARD, V. G., Loosbrock, N., Dickson, D. W., Murphy, M. P., & Golde, T. E. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-24-08532.2003 · Cited by 212 · see citing works

Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration

Wilcock, D. M., Munireddy, S. K., Rosenthal, A., Ugen, K. E., Gordon, M. N., & Morgan, D. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.015 · Cited by 202 · see citing works

Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis

Angelov, D. N., Waibel, S., Guntinas‐Lichius, O., Lenzen, M., Neiss, W. F., Tomov, T. L., Yoles, E., Kipnis, J., Schori, H., Reuter, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530191100 · Cited by 193 · see citing works

Amyloid-β Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients

Patton, R., Kalback, W. M., Esh, C. L., Kokjohn, T. A., Vickle, G. D. V., Luehrs, D. C., Kuo, Y., Lopez, J. C., Brune, D. C., Ferrer, I., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060269 · Cited by 192 · see citing works

Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice

Brendza, R. P., Bacskai, B. J., Cirrito, J. R., Simmons, K. A., Skoch, J. M., Klunk, W. E., Mathis, C. A., Bales, K. R., Paul, S. M., Hyman, B. T., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23269 · Cited by 190 · see citing works

Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears β-amyloid in a mouse model of Alzheimer disease

Frenkel, D., Maron, R., Burt, D. S., & Weiner, H. L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23241 · Cited by 186 · see citing works

Head injury and dementia

Jellinger, K. (2004) · Current Opinion in Neurology · doi:10.1097/00019052-200412000-00012 · Cited by 183 · see citing works

Solution State Characterization of Amyloid β-Derived Diffusible Ligands

Hepler, R. W., Grimm, K. M., Nahas, D. D., Breese, R., Chen-Dodson, E., Acton, P. J., Keller, P. M., Yeager, M. D., Wang, H., Shughrue, P. J., et al. (2006) · Biochemistry · doi:10.1021/bi061850f · Cited by 181 · see citing works

β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease

Buttini, M., Masliah, E., Barbour, R., Grajeda, H., Motter, R., Johnson-Wood, K., Khan, K., Seubert, P., Freedman, S., Schenk, D., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1697-05.2005 · Cited by 176 · see citing works

Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease

Dodel, R. C., Hampel, H. J., Depboylu, C., Lin, S., Gao, F., Schock, S., Jäckel, S., Wei, X., Büerger, K., Höft, C., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10253 · Cited by 161 · see citing works

Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition

Das, P., Murphy, M. P., Younkin, L. H., Younkin, S. G., & Golde, T. E. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00245-7 · Cited by 150 · see citing works

Amyloid-β Antibody Treatment Leads to Rapid Normalization of Plaque-Induced Neuritic Alterations

Lombardo, J. A., Stern, E. A., McLellan, M. E., Kajdasz, S. T., Hickey, G. A., Bacskai, B. J., & Hyman, B. T. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-34-10879.2003 · Cited by 149 · see citing works

Treatment with an Amyloid-β Antibody Ameliorates Plaque Load, Learning Deficits, and Hippocampal Long-Term Potentiation in a Mouse Model of Alzheimer's Disease

Hartman, R. E., Izumi, Y., Bales, K. R., Paul, S. M., Wozniak, D. F., & Holtzman, D. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0664-05.2005 · Cited by 147 · see citing works

Brain Trauma Induces Massive Hippocampal Neuron Death Linked to a Surge in β-Amyloid Levels in Mice Overexpressing Mutant Amyloid Precursor Protein

Smith, D. H., Nakamura, M., McIntosh, T. K., Wang, J., Rodríguez, A., Chen, X.-H., Raghupathi, R., Saatman, K. E., Clemens, J., Schmidt, M. L., et al. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65643-x · Cited by 143 · see citing works

Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies

Lee, M., Bard, F., Johnson‐Wood, K., Lee, C., Hu, K., Griffith, S. G., Black, R. S., Schenk, D., & Seubert, P. A. (2005) · Annals of Neurology · doi:10.1002/ana.20592 · Cited by 129 · see citing works

Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A antibody

Bales, K. R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27120 · Cited by 121 · see citing works

Effect of Different Anti-Aβ Antibodies on Aβ Fibrillogenesis as Assessed by Atomic Force Microscopy

Legleiter, J. A., Czilli, D. L., Gitter, B. D., Demattos, R. B., Holtzman, D. M., & Kowalewski, T. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.11.019 · Cited by 104 · see citing works

Mucosal vaccination delays or prevents prion infection via an oral route

Goñi, F., Knudsen, E., Schreiber, F., Scholtzova, H., Pankiewicz, J. E., Carp, R., Meeker, H. C., Rubenstein, R., Brown, D. R., Sy, M., et al. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.02.031 · Cited by 100 · see citing works

Hormonal Regulation of Growth Plate Cartilage

Savendahl, L. S. (2005) · Hormone Research in Paediatrics · doi:10.1159/000087764 · Cited by 82 · see citing works

Passive Immunization against β-Amyloid Peptide Protects Central Nervous System (CNS) Neurons from Increased Vulnerability Associated with an Alzheimer’s Disease-causing Mutation

Mohajeri, M. H., Saini, K., Schultz, J. G., Wollmer, M. A., Höck, C., & Nitsch, R. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203193200 · Cited by 59 · see citing works

Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now

Lee, V., & Trojanowski, J. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s328 · Cited by 57 · see citing works

Active β-Amyloid Immunization Restores Spatial Learning in PDAPP Mice Displaying Very Low Levels of β-Amyloid

Chen, G., Chen, K. S., Kobayashi, D. T., Barbour, R., Motter, R. N., Games, D., Martin, S. J., & Morris, R. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3710-06.2007 · Cited by 47 · see citing works

Short-term β-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP+PS1 mice.

Austin, L. A., Arendash, G. W., Gordon, M. N., Diamond, D. M., DiCarlo, G., Dickey, C. A., Ugen, K. E., & Morgan, D. (2003) · Behavioral Neuroscience · doi:10.1037/0735-7044.117.3.478 · Cited by 45 · see citing works

Vaccination with prion peptide‐displaying papillomavirus‐like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells

Handisurya, A., Gilch, S., Winter, D., Shafti‐Keramat, S., Maurer, D., Schätzl, H. M., & Kirnbauer, R. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05721.x · Cited by 43 · see citing works

Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS

Haenggeli, C., Julien, J., Mosley, R. L., Perez, N., Dhar, A., Gendelman, H. E., & Rothstein, J. D. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.013 · Cited by 42 · see citing works

The F(ab′)2 fragment of an Aβ-specific monoclonal antibody reduces Aβ deposits in the brain

Tamura, Y., Hamajima, K., Matsui, K., Yanoma, S., Narita, M., Tajima, N., Xin, K.-Q., Klinman, D. M., & Okuda, K. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.04.007 · Cited by 37 · see citing works

Treatment and Prevention of Primary Intracerebral Hemorrhage

Towfighi, A., Greenberg, S. M., & Rosand, J. M. (2005) · Seminars in Neurology · doi:10.1055/s-2005-923538 · Cited by 25 · see citing works

Potential of active and passive immunizations for the prevention and therapy of transmissible spongiform encephalopathies

Bade, S., & Frey, A. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.2.153 · Cited by 16 · see citing works

Herceptin: HERalding a new era in breast cancer care but at what cost?

Hutchinson, L., & DeVita, V. T. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0378 · Cited by 6 · see citing works

Untitled work

Price (1999) · doi:10.1002/1531-8249(199903)45:3

The Amyloid State of Proteins in Human Diseases

Eisenberg, D. S., & Jucker, M. (2012) · Cell · doi:10.1016/j.cell.2012.02.022 · Cited by 1,732 · see citing works

Alzheimer’s Disease: The Challenge of the Second Century

Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424 · see citing works

Alzheimer's disease: strategies for disease modification

Citron, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2896 · Cited by 1,060 · see citing works

The many faces of tau

Morris, M., Maeda, S., Vossel, K., & Mucke, L. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.009 · Cited by 899 · see citing works

Current and future treatments for Alzheimer's disease

Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677 · see citing works

Excitotoxicity: Bridge to various triggers in neurodegenerative disorders

Mehta, A., Prabhakar, M., Kumar, P., Deshmukh, R. R., & Sharma, P. L. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.10.032 · Cited by 662 · see citing works

Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease

Deane, R., Bell, R. D., Sagare, A. P., & Zloković, B. V. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601867 · Cited by 549 · see citing works

Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model

Leinenga, G., & Götz, J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2512 · Cited by 498 · see citing works

Alzheimer’s Disease

de Paula, V. D. J. R., Radanovic, M., Diniz, B. S., & Forlenza, O. V. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-5416-4_14 · Cited by 444 · see citing works

The benefits and limitations of animal models for translational research in neurodegenerative diseases

Jucker, M. (2010) · Nature Medicine · doi:10.1038/nm.2224 · Cited by 401 · see citing works

Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance

Gadhave, D. G., Sugandhi, V. V., Jha, S. K., Nangare, S., Gupta, G., Singh, S. K., Dua, K., Cho, H., Hansbro, P. M., & Paudel, K. R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102357 · Cited by 391 · see citing works

Alzheimer's disease: From immunotherapy to immunoprevention

Jucker, M., & Walker, L. C. (2023) · Cell · doi:10.1016/j.cell.2023.08.021 · Cited by 353 · see citing works

Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models

Chai, X., Wu, S., Murray, T. K., Kinley, R. D., Cella, C. V., Sims, H., Buckner, N., Hanmer, J. M., Davies, P., O’Neill, M. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229633 · Cited by 346 · see citing works

Transgenic mouse models of Alzheimer’s disease.

Elder, G. A., Gama Sosa, M. A., & De Gasperi, R. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20159 · Cited by 336 · see citing works

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

Winblad, B. G., Andreasen, N., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., Maguire, R. P., Blennow, K., Lundmark, J., Staufenbiel, M., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70140-0 · Cited by 311 · see citing works

Cell-to-cell transmission of non-prion protein aggregates

Lee, S., Desplats, P., Sigurdson, C. J., Tsigelny, I. F., & Masliah, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.145 · Cited by 307 · see citing works

Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review

Minati, L., Edginton, T. L., Bruzzone, M. G., & Giaccone, G. (2008) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317508328602 · Cited by 266 · see citing works

Microglia and neuroprotection: From in vitro studies to therapeutic applications

Polazzi, E., & Monti, B. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.009 · Cited by 260 · see citing works

Developing Therapeutic Antibodies for Neurodegenerative Disease

Yu, Y. J., & Watts, R. J. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0187-4 · Cited by 227 · see citing works

Aβ(1–40) forms five distinct amyloid structures whose β-sheet contents and fibril stabilities are correlated

Kodali, R. B., Williams, A. D., Chemuru, S., & Wetzel, R. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.06.023 · Cited by 228 · see citing works

CNS expression of anti‐inflammatory cytokine interleukin‐4 attenuates Alzheimer's disease‐like pathogenesis in APP+PS1 bigenic mice

Kiyota, T., Okuyama, S., Swan, R. J., Jacobsen, M. T., Gendelman, H. E., & Ikezu, T. (2010) · The FASEB Journal · doi:10.1096/fj.10-155317 · Cited by 212 · see citing works

How the Interval between Prime and Boost Injection Affects the Immune Response in a Computational Model of the Immune System

Castiglione, F., Mantile, F., Berardinis, P. D., & Prisco, A. (2012) · Computational and Mathematical Methods in Medicine · doi:10.1155/2012/842329 · Cited by 208 · see citing works

Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach

Zommer, N., Sergeant, N., Schraen-Maschke, S., Blum, D., & Buee, L. (2012) · Current Alzheimer Research · doi:10.2174/156720512800492503 · Cited by 193 · see citing works

Targeting microglia for the treatment of Alzheimer’s Disease

Wes, P. D., Sayed, F. A., Bard, F., & Gan, L. (2016) · Glia · doi:10.1002/glia.22988 · Cited by 185 · see citing works

White Matter Changes in Dementia: Role of Impaired Drainage of Interstitial Fluid

Weller, R. O., Hawkes, C. A., Kalaria, R. N., Werring, D. J., & Carare, R. O. (2014) · Brain Pathology · doi:10.1111/bpa.12218 · Cited by 183 · see citing works

Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives

Lee, S., Lim, H.-S., Masliah, E., & Lee, H.-J. (2011) · Neuroscience Research · doi:10.1016/j.neures.2011.05.008 · Cited by 180 · see citing works

Re-Engineering Biopharmaceuticals for Delivery to Brain with Molecular Trojan Horses

Pardridge, W. M. (2008) · Bioconjugate Chemistry · doi:10.1021/bc800148t · Cited by 168 · see citing works

Induction of Toll-Like Receptor 9 Signaling as a Method for Ameliorating Alzheimer's Disease-Related Pathology

Scholtzova, H., Kascsak, R. J., Bates, K. A., Boutajangout, A., Kerr, D. J., Meeker, H. C., Mehta, P. D., Spinner, D. S., & Wisniewski, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5715-08.2009 · Cited by 166 · see citing works

Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis

Kim, J., Eltorai, A. E. M., Jiang, H., Liao, F., Verghese, P. B., Kim, J., Stewart, F. R., Basak, J. M., & Holtzman, D. M. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20121274 · Cited by 160 · see citing works

Amyloid‐ß‐directed immunotherapy for Alzheimer's disease

Lannfelt, L., Relkin, N. R., & Siemers, E. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12168 · Cited by 157 · see citing works

Amyloid-β immunisation for Alzheimer's disease

Wisniewski, T., & Konietzko, U. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70170-4 · Cited by 155 · see citing works

Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae

Albayram, Ö., Kondo, A., Mannix, R., Smith, C., Tsai, C.-Y., Li, C., Herbert, M. K., Qiu, J., Monuteaux, M. C., Driver, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01068-4 · Cited by 152 · see citing works

New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease

Fuller, J. P., Stavenhagen, J. B., & Teeling, J. L. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00235 · Cited by 154 · see citing works

Surgical excision of CNS‐draining lymph nodes reduces relapse severity in chronic‐relapsing experimental autoimmune encephalomyelitis

van Zwam, M., Huizinga, R., Heijmans, N., van Meurs, M., Wierenga‐Wolf, A. F., Melief, M., Hintzen, R. Q., Hart, B. A. ‘., Amor, S., Boven, L. A., et al. (2008) · The Journal of Pathology · doi:10.1002/path.2476 · Cited by 151 · see citing works

Rapid Microglial Response Around Amyloid Pathology after Systemic Anti-Aβ Antibody Administration in PDAPP Mice

Koenigsknecht-Talboo, J., Meyer-Luehmann, M., Parsadanian, M., Garcia-Alloza, M., Finn, M. B., Hyman, B. T., Bacskai, B. J., & Holtzman, D. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4147-08.2008 · Cited by 149 · see citing works

Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer’s disease

van Olst, L., Simonton, B., Edwards, A. J., Forsyth, A. V., Boles, J. S., Jamshidi, P., Watson, T. H., Shepard, N., Krainc, T., Argue, B. M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03574-1 · Cited by 146 · see citing works

Anti-ApoE Antibody Given after Plaque Onset Decreases Aβ Accumulation and Improves Brain Function in a Mouse Model of Aβ Amyloidosis

Liao, F., Hori, Y., Hudry, E., Bauer, A. Q., Jiang, H., Mahan, T. E., Lefton, K. B., Zhang, T. J., Dearborn, J. T., Kim, J., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0646-14.2014 · Cited by 128 · see citing works

Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies

Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., & Pilotto, A. (2012) · Immunotherapy · doi:10.2217/imt.11.170 · Cited by 125 · see citing works

Intracerebroventricular amyloid-β antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice

Thakker, D. R., Weatherspoon, M. R., Harrison, J., Keene, T. E., Lane, D. S., Kaemmerer, W. F., Stewart, G. R., & Shafer, L. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813404106 · Cited by 124 · see citing works

The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation

Castellani, R. J., Plascencia‐Villa, G., & Perry, G. L. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0231-z · Cited by 124 · see citing works

Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease

Agbo, D. B., Wolf, E., Jessen, F., Oechsner, M., Hametner, E., Poewe, W. H., Reindl, M., Oertel, W. H., Noelker, C., Bacher, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31827b90d1 · Cited by 120 · see citing works

Robust amyloid clearance in a mouse model of Alzheimer’s disease provides novel insights into the mechanism of amyloid-β immunotherapy

Wang, A., Das, P., Switzer, R. C., Golde, T. E., & Jankowsky, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5077-10.2011 · Cited by 118 · see citing works

Detection of Amyloid Plaques Targeted by Bifunctional USPIO in Alzheimer’s Disease Transgenic Mice Using Magnetic Resonance Microimaging

Wadghiri, Y. Z., Li, J., Wang, J., Hoang, D. M., Sun, Y., Xu, H., Tsui, W., Li, Y., Boutajangout, A., Wang, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057097 · Cited by 114 · see citing works

Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease

Yamin, G., Ono, K., Inayathullah, M., & Teplow, D. B. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786404137 · Cited by 111 · see citing works

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

Dodel, R. C., Neff, F., Noelker, C., Pul, R., Du, Y., Bacher, M., & Oertel, W. H. (2010) · Drugs · doi:10.2165/11533070-000000000-00000 · Cited by 110 · see citing works

Inhibiting ACAT1/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases Aβ1-42 clearance

Shibuya, Y., Chang, C. C. Y., Huang, L.-H., Bryleva, E. Y., & Chang, T.-Y. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.2567-14.2014 · Cited by 108 · see citing works

Identification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease

Wirths, O., Erck, C., Martens, H., Harmeier, A., Geumann, C., Jawhar, S., Kumar, S., Multhaup, G., Walter, J., Ingelsson, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.178707 · Cited by 103 · see citing works

Microglial Activation in Alzheimers Disease

Schlachetzki, J. C. M., & Hüll, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509790147179 · Cited by 102 · see citing works

Transcranial optical imaging reveals a pathway for optimizing the delivery of immunotherapeutics to the brain

Plog, B. A., Mestre, H., Olveda, G. E., Sweeney, A. M., Kenney, H. M., Cove, A., Dholakia, K. Y., Tithof, J., Nevins, T. D., Lundgaard, I., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120922 · Cited by 101 · see citing works

Combined Treatment with a BACE Inhibitor and Anti-Aβ Antibody Gantenerumab Enhances Amyloid Reduction in APP London Mice

Jacobsen, H., Ozmen, L., Caruso, A., Narquizian, R., Hilpert, H., Jacobsen, B., Terwel, D., Tanghe, A., & Bohrmann, B. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1405-14.2014 · Cited by 96 · see citing works

Calcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures

Chakroborty, S., & Stutzmann, G. E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.012 · Cited by 91 · see citing works

Amyloid-β Immunotherapy for Alzheimers Disease

Fu, H., Liu, B., Frost, J. L., & Lemere, C. A. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012017 · Cited by 91 · see citing works

The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics

Pritchard, S. M., Dolan, P. J., Vitkus, A., & Johnson, G. V. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01273.x · Cited by 89 · see citing works

Improvement of spatial learning by facilitating large-conductance calcium-activated potassium channel with transcranial magnetic stimulation in Alzheimer's disease model mice

Wang, F., Zhang, Y., Wang, L., Sun, P., Luo, X., Ishigaki, Y., Sugai, T., Yamamoto, R., & Kato, N. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.05.027 · Cited by 87 · see citing works

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β

Vogt, A. S., Jennings, G. T., Mohsen, M. O., Vogel, M., & Bachmann, M. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043895 · Cited by 86 · see citing works

Blood Plasma IgG Fc Glycans are Significantly Altered in Alzheimer's Disease and Progressive Mild Cognitive Impairment

Lundström, S. L., Yang, H., Lyutvinskiy, Y., Rutishauser, D., Herukka, S., Soininen, H. S., & Zubarev, R. A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-131088 · Cited by 83 · see citing works

Murine models of Alzheimer's disease and their use in developing immunotherapies

Wısnıewskı, T., & Sigurdsson, E. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.05.004 · Cited by 80 · see citing works

Peripheral Amyloid-β Levels Regulate Amyloid-β Clearance from the Central Nervous System

Marques, M. A., Kulstad, J. J., Savard, C. E., Green, P. S., Lee, S. P., Craft, S., Watson, G. S., & Cook, D. G. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0964 · Cited by 77 · see citing works

APP transgenic mice: their use and limitations

Balducci, C., & Forloni, G. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-010-8141-7 · Cited by 79 · see citing works

Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer’s pathology: Insights and therapeutic approaches from periphery

Ullah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78 · see citing works

Aβ-oligomers: A potential therapeutic target for Alzheimer's disease

Ghosh, S., Ali, R., & Verma, S. K. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124231 · Cited by 79 · see citing works

Soluble amyloid-β, effect on cerebral arteriolar regulation and vascular cells

Dietrich, H. H., Xiang, C., Han, B. H., Zipfel, G. J., & Holtzman, D. M. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-15 · Cited by 77 · see citing works

Autoimmune and inflammatory mechanisms of CNS damage

Kapadia, M., & Šakić, B. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.008 · Cited by 75 · see citing works

Systemic vaccination with anti‐oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg‐AD mice

Rasool, S., Martínez‐Coria, H., Wu, J., LaFerla, F. M., & Glabe, C. G. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12305 · Cited by 74 · see citing works

Current pharmacotherapy and putative disease-modifying therapy for Alzheimer’s disease

Kulshreshtha, A., & Piplani, P. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2625-7 · Cited by 75 · see citing works

Potential of the Antibody Against cis–Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury

Lu, K. P., Kondo, A., Albayram, Ö., Herbert, M. K., Liu, H., & Zhou, X. Z. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2027 · Cited by 74 · see citing works

Toward Therapy of Human Prion Diseases

Aguzzi, A., Lakkaraju, A. K., & Frontzek, K. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052745 · Cited by 74 · see citing works

Chronic Intranasal Treatment with an Anti-Aβ30-42 scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease

Cattepoel, S., Hanenberg, M., Kulic, L., & Nitsch, R. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018296 · Cited by 73 · see citing works

Autoantibodies Against Amyloid and Glial-Derived Antigens are Increased in Serum and Cerebrospinal Fluid of Lewy Body-Associated Dementias

Maetzler, W., Berg, D., Synofzik, M., Brockmann, K., Godau, J., Melms, A., Gasser, T., Hörnig, S., & Langkamp, M. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110221 · Cited by 72 · see citing works

The consequences of mitochondrial amyloid β-peptide in Alzheimer's disease

Muirhead, K. E. A., Borger, E., Aitken, L., Conway, S. J., & Gunn‐Moore, F. J. (2010) · Biochemical Journal · doi:10.1042/bj20091941 · Cited by 66 · see citing works

Nanomedicine-based immunotherapy for central nervous system disorders

Hanif, S., Muhammad, P., Chesworth, R., Rehman, F. U., Qian, R., Zheng, M., & Shi, B. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0429-z · Cited by 68 · see citing works

Noninvasive Magnetic Resonance Imaging Detection of Cerebral Amyloid Angiopathy-Related Microvascular Alterations Using Superparamagnetic Iron Oxide Particles in APP Transgenic Mouse Models of Alzheimer's Disease: Application to Passive Aβ Immunotherapy

Beckmann, N., Gérard, C., Abramowski, D., Cannet, C., & Staufenbiel, M. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.4936-10.2011 · Cited by 65 · see citing works

Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy

Pérez-Garmendia, R., & Gevorkian, G. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311050004 · Cited by 65 · see citing works

Elevated Osteopontin Levels in Mild Cognitive Impairment and Alzheimer's Disease

Sun, Y., Yin, X.-S., Guo, H., Han, R.-K., He, R.-D., & Chi, L. (2013) · Mediators of Inflammation · doi:10.1155/2013/615745 · Cited by 63 · see citing works

Targeting β-Amyloid Pathology in Alzheimer's Disease with Aβ Immunotherapy

Nitsch, R. M., & Höck, C. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.013 · Cited by 62 · see citing works

Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders

Neff, F., Wei, X., Noelker, C., Bacher, M., Du, Y., & Dodel, R. C. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.04.010 · Cited by 62 · see citing works

Inflammation and Microglia Actions in Alzheimer’s Disease

Combs, C. K. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9165-3 · Cited by 61 · see citing works

Bapineuzumab: Anti-β-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer‘s Disease

Panza, F., Frisardi, V., Imbimbo, B. P., D’Onofrio, G., Pietrarossa, G., Seripa, D., Pilotto, A., & Solfrizzi, V. (2010) · Immunotherapy · doi:10.2217/imt.10.80 · Cited by 58 · see citing works

Antibody-based therapy in Alzheimer's disease

Pul, R., Dodel, R. C., & Stangel, M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.552884 · Cited by 58 · see citing works

Alzheimers Disease: Pathological Mechanisms and Recent Insights

Niedowicz, D. M., Nelson, P. T., & Murphy, M. P. (2011) · Current Neuropharmacology · doi:10.2174/157015911798376181 · Cited by 58 · see citing works

Allele-specific RNAi Mitigates Phenotypic Progression in a Transgenic Model of Alzheimer's Disease

Rodríguez-Lebrón, E., Gouvion, C. M., Moore, S. A., Davidson, B. L., & Paulson, H. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.123 · Cited by 54 · see citing works

Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease

Basi, G. S., Hemphill, S. S., Brigham, E. F., Liao, A., Aubele, D. L., Baker, J., Barbour, R., Bova, M. P., Chen, X., Dappen, M. S., et al. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt60 · Cited by 53 · see citing works

A Death Receptor 6-Amyloid Precursor Protein Pathway Regulates Synapse Density in the Mature CNS But Does Not Contribute to Alzheimer's Disease-Related Pathophysiology in Murine Models

Kallop, D. Y., Meilandt, W. J., Gogineni, A., Easley‐Neal, C., Wu, T. Z., Jubb, A. M., Yaylaoglu, M., Shamloo, M., Tessier‐Lavigne, M., Scearce-Levie, K. A., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.4963-13.2014 · Cited by 52 · see citing works

Nature and Nurture of Catalytic Antibodies

Paul, S., Planque, S. A., Nishiyama, Y., Hanson, C. V., & Massey, R. J. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3461-0_5 · Cited by 53 · see citing works

Cognitive recovery by chronic activation of the large-conductance calcium-activated potassium channel in a mouse model of Alzheimer's disease

Wang, L., Kang, H., Li, Y., Shui, Y., Yamamoto, R., Sugai, T., & Kato, N. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.12.033 · Cited by 49 · see citing works

Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers

Robert, R., Dolezal, O., Waddington, L. J., Hattarki, M. K., Cappai, R., Masters, C. L., Hudson, P. J., & Wark, K. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn052 · Cited by 52 · see citing works

Vaccination as a Therapeutic Approach to Alzheimer's Disease

Wısnıewskı, T., & Boutajangout, A. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20156 · Cited by 51 · see citing works

Antibody Therapeutics Targeting Aβ and TauPreprint

Gallardo, G., & Holtzman, D. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024331 · Cited by 51 · see citing works

Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species

Vugmeyster, Y., Szklut, P., Wensel, D. L., Ross, J. E., Xu, X., Awwad, M., Gill, D. S., Tchistiakov, L., & Warner, G. L. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0405-x · Cited by 50 · see citing works

APOE: The New Frontier in the Development of a Therapeutic Target towards Precision Medicine in Late-Onset Alzheimer’s

Yang, A., Kantor, B., & Chiba‐Falek, O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031244 · Cited by 47 · see citing works

The evolving landscape of Alzheimer’s disease therapy: From Aβ to tau

Courade, J., Zetterberg, H., Höglinger, G. U., & Dewachter, I. (2025) · Cell · doi:10.1016/j.cell.2025.11.033 · Cited by 52 · see citing works

Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease

Laurent, S., Ejtehadi, M. R., Rezaei, M., Kehoe, P. G., & Mahmoudi, M. (2012) · RSC Advances · doi:10.1039/c2ra01374f · Cited by 49 · see citing works

Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies

Rockenstein, E. M., Ostroff, G. R., Dikengil, F., Rus, F., Mante, M., Florio, J. B., Adame, A., Trinh, I., Kim, C., Overk, C., et al. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1170-17.2017 · Cited by 49 · see citing works

Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders

Guo, Z.-H., Khattak, S., Rauf, M. A., Ansari, M. A., Alomary, M. N., Razak, S., Yang, C., Wu, D., & Ji, X. (2023) · Molecules · doi:10.3390/molecules28031283 · Cited by 49 · see citing works

Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease

Kalra, J., & Khan, A. G. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.07.043 · Cited by 47 · see citing works

Recombinant Antibody Fragments for Neurodegenerative Diseases

Manoutcharian, K., Pérez-Garmendia, R., & Gevorkian, G. (2016) · Current Neuropharmacology · doi:10.2174/1570159x01666160930121647 · Cited by 46 · see citing works

Immunotherapy in prion disease

Roettger, Y., Du, Y., Bacher, M., Zerr, I., Dodel, R. C., & Bach, J. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.258 · Cited by 44 · see citing works

Alzheimer’s Disease: Drug Discovery

Huang, X. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020 · Cited by 45 · see citing works

Moving towards a vaccine

Holtzman, D. M. (2008) · Nature · doi:10.1038/454418a · Cited by 44 · see citing works

Intraneuronal Aβ as a trigger for neuron loss: can this be translated into human pathology?

Bayer, T. A., & Wirths, O. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390857 · Cited by 41 · see citing works

Innovative Therapie der Alzheimer-Demenz

Dodel, R. C., & Bacher, M. (2008) · Der Nervenarzt · doi:10.1007/s00115-008-2499-x · Cited by 1 · see citing works

Clinical immunotherapy trials in Alzheimer’s disease

Hawkes, C. A., & McLaurin, J. (2008) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.09.004 · Cited by 8 · see citing works

Immunotherapeutic Approaches for the Treatment of Neurodegenerative Diseases: Challenges and Outcomes

Mondal, A. C., & Sushma (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666211228100955 · Cited by 4 · see citing works

Immunotherapy: An emerging treatment option for neurodegenerative diseases

Mukherjee, A., Biswas, S., & Roy, I. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103974 · Cited by 21 · see citing works

Immunotherapy for neurodegenerative diseases: the Alzheimer's disease paradigm

Montoliu‐Gaya, L., & Villegas, S. (2018) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2017.12.006 · Cited by 9 · see citing works